Hyperion DeFi (HYPD) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
13 Aug, 2026Executive summary
Achieved record net income and adjusted EBITDA in Q2 2026, driven by HYPE token appreciation, scalable DeFi businesses, and cost reductions, marking a full transition from legacy biotech to a DeFi-native model.
Gross HYPE Holdings rose to $132.6M, up 87% quarter-over-quarter and 192% year-over-year, with five business lines contributing to a 162% year-over-year increase in adjusted gross profit.
Operating expenses excluding stock-based compensation declined 46% year-over-year to $2.3M, reflecting the wind-down of the legacy segment.
Expanded institutional partnerships, including Blockdaemon for staking and Skew/Entropy for permissionless market deployments, and completed the first institutional on-chain credit deal via HyperLend Aviya.
Fully exited legacy ophthalmic and biotech operations, selling all related IP and extinguishing liabilities.
Financial highlights
Q2 2026 net income: $31.0M (vs. $8.8M in Q1 2026); adjusted EBITDA: $53.7M (vs. $19.5M in Q1 2026).
Adjusted gross profit grew 20% sequentially to $1.15M in Q2 2026, with 50% earned in cash or equivalents.
Gross HYPE tokens increased 56% year-over-year to 2.04M.
Net asset value rose to $134.2M as of June 30, 2026.
Cash, cash equivalents, and stablecoins totaled $11.8M at quarter-end.
Outlook and guidance
2026 adjusted gross profit guidance reiterated at $5M–$7M, approximately 5x 2025 results.
Adjusted net operating cash flow expected to turn positive by year-end 2026.
Management expects existing resources to fund operations for at least the next 12 months.
Latest events from Hyperion DeFi
- Q1 2026 net income $8.8M, adjusted gross profit up 17%, guidance raised to $5M–$7M.HYPD
Q1 2026 - Five key proposals, governance updates, and major transactions highlighted for the 2026 meeting.HYPD
Proxy filing - Virtual meeting to vote on directors, auditor, compensation, and written consent amendment.HYPD
Proxy filing - Five key proposals, governance updates, and compensation details set for the 2026 annual meeting.HYPD
Proxy filing - Q4 adjusted gross profit jumped 87% QoQ, with 2026 guidance targeting 4x FY 2025 results.HYPD
Q4 2025 - All recent capital is used to build a HYPE token reserve, exposing the business to crypto volatility.HYPD
Registration Filing - Shelf registration allows up to $100M in offerings, including $25M at-the-market sales via Leerink Partners.HYPD
Registration Filing - Q3 net loss was $7.9M as clobetasol launched, MydCombi expanded, and liquidity risks persisted.HYPD
Q3 2024 - Q2 net loss rose to $11.1M as cash fell and late-stage ophthalmic programs advanced.HYPD
Q2 2024